IP Library Granted Patent US 9,023,879
Granted Patent B2
US 9,023,879 · App. 13/925,507 · Granted May 5, 2015

Specific diarylhydantoin and diarylthiohydantoin compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,023,879
App. No.
13/925,507
Granted
May 5, 2015
Kind
B2
Abstract

Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.

Claims (27)

1. A method of treating prostate cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a unit dosage amount of a compound of the formula I:

wherein X is S or O, and

when X is S then R 1 is OH or NH 2 ; and

when X is O then R 1 is OH, NH 2 or NHMe,

or a pharmaceutically acceptable salt or solvate thereof.

2. The method of claim 1 , wherein X is S and R 1 is OH or NH 2 .

3. The method of claim 1 , wherein X is O and R 1 is OH, NH 2 or NHMe.

4. The method of claim 1 , wherein the compound is

5. The method of claim 1 , wherein the compound is:

6. The method of claim 1 , wherein the compound is:

7. The method of claim 1 , wherein the compound is:

8. The method of claim 1 , wherein the compound is:

9. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

10. A pharmaceutical composition, comprising:

(a) a unit dosage amount of a compound of the formula I:

wherein X is S or O, and

when X is S then R 1 is OH or NH 2 ; and

when X is O then R 1 is OH, NH 2 or NHMe,

or a pharmaceutically acceptable salt or solvate thereof; and

(b) a pharmaceutically acceptable vehicle.

11. The pharmaceutical composition of claim 10 , wherein X is S and R 1 is OH or NH 2 .

12. The pharmaceutical composition of claim 10 , wherein X is O and R 1 is OH, NH 2 or NHMe.

13. The pharmaceutical composition of claim 10 , wherein the compound is

14. The pharmaceutical composition of claim 10 , wherein the compound is:

15. The pharmaceutical composition of claim 10 , wherein the compound is:

16. The pharmaceutical composition of claim 10 , wherein the compound is:

17. The pharmaceutical composition of claim 10 , wherein the compound is:

Assignments (7)
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Mar 16, 2023
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 063825/0313 →
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Apr 2, 2021
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 055812/0386 →
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Feb 11, 2021
From: MEDIVATION PROSTATE THERAPEUTICS LLC
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 055280/0364 →
ARTICLES OF ORGANIZATION-CONVERSION Recorded Mar 15, 2018
From: MEDIVATION PROSTATE THERAPEUTICS, INC.
To: MEDIVATION PROSTATE THERAPEUTICS LLC
Reel/Frame 045616/0241 →
RELEASE OF SECURITY INTEREST Recorded Sep 28, 2016
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MEDIVATION PROSTATE THERAPEUTICS, INC.; MEDIVATION TECHNOLOGIES, INC.
Reel/Frame 040181/0177 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 4, 2015
From: MEDIVATION PROSTATE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036553/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2013
From: JAIN, RAJENDRA PARASMAL; GIBBONS, JACQUELINE A.
To: MEDIVATION PROSTATE THERAPEUTICS, INC.
Reel/Frame 030676/0867 →